Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Essai clinique sur la kynurénine pour l’EM / SFC

L’Open Medicine Foundation est heureuse d’annoncer son soutien au lancement d’un essai clinique visant à comprendre les perturbations potentielles du métabolisme du tryptophane et à tester les avantages du traitement des personnes atteintes d’EM/SFC par la kynurénine. La kynurénine est naturellement produite dans l’organisme, et constitue un métabolite clé dans le métabolisme du tryptophane. Elle joue plusieurs rôles dans le système immunitaire et l’inflammation. L’essai clinique sur la kynurénine sera mené au centre de recherche collaboratif sur l’EM/SFC de l’université d’Uppsala, sous la supervision du Dr Jonas Bergquist. L’OMF a apporté son soutien pour lancer cette recherche dans une étude croisée randomisée, en double aveugle et contrôlée par placebo. Le but de l’étude est d’évaluer si la kynurénine est directement liée à la gravité des symptômes des patients atteints d’EM/SFC.

Les participants seront randomisés pour recevoir soit de la kynurénine soit un placebo pendant une période de trois mois, puis, après une période d’élimination, les patients passeront à trois mois supplémentaires de kynurénine ou de placebo dans le cadre d’un protocole croisé. Ce modèle ne nécessite pas de contrôles sains et vise plutôt à déterminer si la supplémentation en kynurénine présente un avantage quelconque par rapport au placebo chez les personnes atteintes d’EM/SFC. Les principaux paramètres de l’étude seront les effets de la supplémentation en Kynurénine pour améliorer les troubles cognitifs (« brouillard cérébral »), la mémoire et les maux de tête. Les patients seront également invités à enregistrer leur activité en utilisant des capteurs portables.

Actuellement, de nouvelles méthodes ont été développées sous la direction du Dr Bergquist pour mesurer les voies métaboliques pertinentes pour la Kynurénine. Ces nouvelles méthodes sont utilisées pour identifier 20 personnes atteintes d’EM/SFC qui ont une faible teneur en kynurénine dans le plasma à partir d’un échantillon de plus de 100 personnes. Cette méthode sera également utilisée pour surveiller les effets métaboliques de la supplémentation en kynurénine pendant l’essai.

L’étude de ces caractéristiques améliorera notre compréhension de l’EM/SFC et cet essai clinique pourrait déboucher sur de nouvelles options thérapeutiques pour les personnes atteintes d’EM/SFC.

Cet essai clinique pourrait déboucher sur de nouvelles options thérapeutiques pour les patients atteints d’EM / SFC

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo